Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus
Open Access
- 6 November 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2571
Abstract
Pemphigus, an autoimmune blistering disease that affects the skin and mucous membranes, adversely impacts patients’ quality of life (QOL). While there are various QOL measurement tools that can be used in this disease, few studies have assessed how a patient’s change in disease severity can affect their QOL. This study aims to identify which disease severity index correlates best with the change in QOL. Fifty pemphigus patients completed QOL surveys with disease severity scored over two visits. QOL was assessed with the Autoimmune Bullous Disease Quality of Life (ABQOL), Dermatology Life Quality Index (DLQI), Skindex-29, and Short Form Survey 36 (SF-36). Disease severity was scored with the Pemphigus Disease Activity Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). Correlations between the change in QOL scores and change in disease severity were analyzed using Spearman’s coefficient (r). The change in PDAI showed a strong correlation (r=0.60-0.79) with changes in the ABQOL, Skindex-29 symptoms (Skindex-S) and Skindex-29 functioning (Skindex-F) subscales for all patients (n=50). For patients with mucosal disease (n=24), the change in PDAI showed a strong correlation with changes in the ABQOL and Skindex-S subscale. For patients without mucosal disease, the change in PDAI showed a strong correlation with the Skindex-S. The change in ABSIS showed a strong correlation with Skindex-S for all patients and patients with no mucosal involvement, but showed no strong correlations for patients with mucosal involvement. The changes in PDAI always had a stronger correlation than the changes in ABSIS scores to changes in the ABQOL, DLQI, and Skindex-29 subscales, except where the PDAI and ABSIS scores were about the same for the Skindex-S subscale in patients with no mucosal involvement (r=0.76 and r=0.77 respectively). PDAI is superior to ABSIS in its correlation with validated QOL tools. The QOL tools that appear to be of most use in clinical trials and patient management are the Skindex-S and ABQOL.Keywords
This publication has 38 references indexed in Scilit:
- Severity score indexes for blistering diseasesClinics in Dermatology, 2012
- Quality of life in patients with bullous dermatosesClinics in Dermatology, 2012
- Reliability and Convergent Validity of Two Outcome Instruments for PemphigusJournal of Investigative Dermatology, 2009
- The Co‐Occurrence of Chronic Diseases and Geriatric Syndromes: The Health and Retirement StudyJournal of the American Geriatrics Society, 2009
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- Dermatology Quality of Life Instruments: Sorting Out the QuagmireJournal of Investigative Dermatology, 2007
- Cutaneous symptoms of dermatomyositis significantly impact patients' quality of lifeJournal of the American Academy of Dermatology, 2006
- Deutliche Einschränkung der Lebensqualität bei Patienten mit Pemphigus vulgaris: Ergebnisse der deutschen Bullous Skin Disease (BSD)‐StudiengruppeJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2005
- Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trialJournal of the American Academy of Dermatology, 2003
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992